**Supporting material 1.** Characteristics of studies included in the meta-ana

PMID	AUTHOR	YEAR	COUNTRY	Ethnicity	SAMPLE SIZE
32217556	Chen T	2020	China	Chinese	274
32217650	Guan WJ	2020a	China	Chinese	1590
32269088	Du RH	2020	China	Chinese	179
32188484	Shi Y	2020	China	Chinese	487
32294485	Li XC	2020	China	Chinese	548
32304745	Zhang JX	2020	China	Chinese	663
31986264	Huang CL	2020	China	Chinese	41
32031570	Wang DW	2020	China	Chinese	138
32105632	Yang XB	2020	China	Chinese	52
32109013	Guan WJ	2020b	China	Chinese	1099
32167524	Wu CM	2020	China	Chinese	201
32171076	Zhou F	2020	China	Chinese	191
32191764	Yuan ML	2020	China	Chinese	27

32173725	Mo PZ	2020	China	Chinese	155
32176772	Wang ZL	2020	China	Chinese	69
32409504	Shi Q	2020	China	Chinese	306
32564693	laccarino G	2020	Italy	Italian	1591

## **CASE CHARACTERISTICS**

mean age 62 years; 171 males, 103 females; <40 years 53, 40-60 years 68,  $\ge$ 60 years 153

mean age: 48.9±16.3 years; 904 males; 674 females

mean age 57.6 $\pm$ 13.7 years; 97 males, 82 females; 0-49 years 49, 50-64 years 65;  $\geqslant$ 65 years 65

mean age 46 years; 259 males, 228 females

mean age 60 years; 279 males, 269 females; 0-44 years 107, 45-64 years 231, ≥65 years 210

mean age 55.6 years; 321 males, 342 females; 0-60 years 348, > 60 years 315

mean age 49 years; 30 males, 11 females

mean age 56 years; 75 males, 63 females

mean age 59.7 years; 35 males, 17 females; 30-60 years 25, >60 years 27

mean age: 47 years; 639males; 460 females; 0-65 years 849; ≥65 years 153

mean age 51 years; 128 males, 73 females

mean age 56 years; 119 males, 72 females

mean age 56 years; 12 males, 15 females

mean age 54 years; 86 males, 69 females

mean age 42 years; 32 males, 37 females

Patients without diabetes: mean age 65 years; Patients with diabetes: mean age 64 years; each group: 75 males, 78 females mean age 66.5±0.4 years; 1018 males, 573 females

## Study design

A retrospective study obtained epidemiological, clinical, laboratory, and radiological characteristics, as well as treatment and outcome data, from electronic medical records for deceased patients and recovered patients by using data collection forms.

A retrospective case study compiled the clinical data of laboratory-confirmed hospitalized cases from 575 hospitals between December 11<sup>th</sup>, 2019 and January 31<sup>st</sup>, 2020

The written informed consent from each patient was waived since we prospectively collected and analyzed all data from each patient according to the policy for public health outbreak investigation of emerging infectious diseases issued by the National Health Commission of the People's Republic of China.

A retrospective study obtained medical records, laboratory findings, and pulmonary CT scan of each patient with COVID-19, provided by the local health authority and inputted into a pre-specified electronic data collection form.

The epidemiological and demographic data were obtained by face-to-face or telephone interview. Clinical symptoms, laboratory, and radiological findings on admission as well as the complications, treatment and outcomes during hospitalization were extracted from electronic medical records.

A retrospective study obtained oral informed consent from all patients enrolled in the study.

Local centres for disease control and prevention collected respiratory, blood, and faeces specimens, then shipped them to designated authoritative laboratories to detect the pathogen.

The datawere reviewed by a trained team of physicians. Information recorded included demographic data, medical history, exposure history, underlyingcomorbidities, symptoms, signs, laboratory findings, chest computed tomographic (CT) scans, and treatment measures (ie, antiviral therapy, corticosteroid therapy, respiratory support, kidney replacement therapy).

The retrospective, observational study obtained clinical electronic medical records, nursing records, laboratory findings, and radiological examinations for all patients with laboratory confirmed SARS-CoV-2 infection.

The study obtained the medical records and compiled data for hospitalized patients and outpatients with laboratory-confirmed Covid-

A trained team of physicians and medical students reviewed and collected epidemiological, clinical, and outcomes data from electronic medical records.

Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardised data collection form.

Clinical characteristics together with chest imaging manifestations of each confirmed cases were recorded.

A COVID-19 case report form was designed to document primary data regarding demographic, clinical, laboratory, radiological and therapeutic characteristics from electronic medical records

The study obtaines clinical charts, nursing records, laboratory results, and chest CT characteristics for all patients.

Epidemiological, demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardised data collection form.

An online questionnaire was distributed among the centers to collect reviewed epidemiological, clinical, and outcomes data from hospital emergency rooms and regular and intensive care wards.

Clinical typing of COVID-19(No)	Young age( <60 or <65 years)	advanced age	Male  Recovered patients: 88;  Deaths: 83	
Recovered patients: 161; Deaths: 113	Recovered patients: 102; Deaths: 19	Recovered patients: 59; Deaths: 94		
Mild: 1286; Severe: 254; Deaths: 50	-	-	-	
Deceased: 21; Survivors: 158	Survivors: 110; Deceased: 4	Survivors: 48; Deceased: 17	Survivors: 87; Deceased: 10	
Mild: 438; Severe: 49	-	-	Mild: 223; Severe: 36	
Nonsevere: 279; Severe: 269	Nonsevere: 204; Severe: 134	Nonsevere: 75; Severe: 135	Nonsevere: 126; Severe: 153	
Mild to Moderate: 254; Severe: 315; Critical: 94; Survival: 638, Non-survi val: 25	Mild to Moderate: 185; Severe: 136; Critical: 27; Survival: 342, Non-survi val: 6	Mild to Moderate: 69; Severe: 179; Critical: 67; Survival: 296, Non-survival: 19	Mild to Moderate: 116; Severe: 149; Critical: 56; Survival: 306, Non-survi val: 15	
Mild: 28; Severe: 13	-	-	Mild: 19; Severe: 11	
Mild: 102; Severe: 36	-	-	Mild: 53; Severe: 22	
Deceased: 32; Survivors: 20	Survivors: 13; Deceased: 12	Survivors: 7; Deceased: 20	Survivors: 14; Deceased: 21	
Mild: 926; Severe: 173	Mild: 739; Severe: 119	Mild: 109; Severe: 44	Mild: 537; Severe: 100	
Mild: 117; Severe: 84	-	-	Mild: 68; Severe: 60	
Deceased: 54; Survivors: 137	-	-	Survivors: 81; Deceased: 38	
Survivors: 17; Deceased: 10	-	-	Survivors: 8; Deceased: 4	

Mild: 70; Severe: 85	-	- Mild: 31; Severe: 55
Mild: 55; Severe: 14	-	- Mild: 15; Severe: 7
Survival: 259; Death: 47	-	- Survivors: 122; Death: 28
Nonsurvivors: 188; Survivors: 1403	-	

Female	Smoking	No Smoking	Chronic lung diseases	
Recovered patients: 73; Deaths: 30	Recovered patients: 10; Deaths: 9	Recovered patients: 151; Deaths: 104	Recovered patients: 7; Deaths: 11	
-	-	-	Mild: 3; Severe: 15; Deaths: 6	
Survivors: 71; Deceased: 11	-	-	-	
Mild: 215; Severe: 13	Mild: 34; Severe: 6	Mild: 391; Severe: 43	-	
Nonsevere: 153; Severe: 116	Nonsevere: 41; Severe: 51	Nonsevere: 238; Severe: 214	Nonsevere: 4; Severe: 13	
Mild to Moderate: 138; Severe: 166; Critical: 38; Survival: 332, Non-survi val: 10	-	-	Mild to Moderate: 13; Severe: 23; Critical: 15; Survival: 46, Non-survi val: 5	
Mild: 9; Severe: 2	-	-	Mild: 0; Severe: 1	
Mild: 51; Severe: 14	-	-	Mild: 1; Severe: 3	
Survivors: 6; Deceased: 11	-	-	Survivors: 2; Deceased: 2	
Mild: 386; Severe: 73	Mild: 120; Severe: 38	Mild: 793; Severe: 134	Mild: 6; Severe: 6	
Mild: 49; Severe: 24	-	-	-	
Survivors: 56; Deceased: 16	-	-	Survivors: 2; Deceased: 4	
Survivors: 9; Deceased: 6	-	-	Survivors: 1; Deceased: 10	

Mild: 39; Severe: 30	-	-	Mild: 0; Severe: 4
Mild: 30; Severe: 7	-	-	Mild: 2; Severe: 2
Survivors: 137; Death: 19	-	-	Survivors: 14; Death: 7
-	-	-	Nonsurvivors: 28; Survivors: 94

Diabetes	Hypertension	Chronic kidney disease	Cardiovascular disease	ТҮРЕ
Recovered patients: 23; Deaths: 24	Recovered patients: 39; Deaths: 54	Recovered patients: 1; Deaths: 4	Recovered patients: 7; Deaths: 16	retrospective cohort
Mild: 72; Severe: 45; Deaths: 13	Mild: 153; Severe: 88; Deaths: 28	Mild: 8; Severe: 8; Deaths: 5	Mild: 31; Severe: 20; Deaths: 8	retrospective cohort
Survivors: 27; Deceased: 6	Survivors: 45; Deceased: 13	-	Survivors: 17; Deceased: 12	retrospective cohort
Mild: 22; Severe: 7	Mild: 73; Severe: 26	Mild: 5; Severe: 2	Mild: 7; Severe: 4	retrospective cohort
Nonsevere: 31; Severe: 52	Nonsevere: 62; Severe: 104	Nonsevere: 4; Severe: 6	Nonsevere: 6; Severe: 28	ambispective cohort
Mild to Moderate: 14; Severe: 39; Critical: 14; Survival: 64, Non-survi val: 5	-	-	Mild to Moderate: 33; Severe: 82; Critical: 49; Survival: 148, Non-survival: 16	retrospective cohort
Mild: 7; Severe: 1	Mild: 4; Severe: 2	-	Mild: 3; Severe: 3	retrospective cohort
Mild: 6; Severe: 8	Mild: 22; Severe: 21	Mild: 2; Severe: 2	Mild: 11; Severe: 9	retrospective cohort
Survivors: 2; Deceased: 7	-	-	Survivors: 2; Deceased: 3	retrospective cohort
Mild: 53; Severe: 28	Mild: 124; Severe: 41	Mild: 5; Severe: 3	Mild: 17; Severe: 10	retrospective cohort
Mild: 6; Severe: 16	Mild: 16; Severe: 23	-	Mild: 3; Severe: 5	retrospective cohort
Survivors: 19; Deceased: 17	Survivors: 32; Deceased: 26	Survivors: 0; Deceased: 2	Survivors: 2; Deceased: 13	retrospective cohort
Survivors: 0; Deceased: 6	Survivors: 0; Deceased: 5	-	Survivors: 0; Deceased: 3	retrospective

Mild: 3; Severe: 12	Mild: 15; Severe: 22	Mild: 2; Severe: 4	Mild: 0; Severe: 14	retrospective
Mild: 1; Severe: 6	Mild: 4; Severe: 5	-	Mild: 3; Severe: 5	retrospective
Survivors: 122; Death: 31	Survivors: 99; Death: 32	Survivors: 7; Death:	Survivors: 32; Death: 17	retrospective
Nonsurvivors: 61; Survivors: 208	Nonsurvivors: 137; Survivors: 737	Nonsurvivors: 31; Survivors: 56	Nonsurvivors: 56; Survivors: 160	cross-sectional

Studies quality (AHQR or NOS)
7
8
8
7
8
7
7
7
7
8
7
8
7